Wednesday, April 29, 2020

First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalized patients who are critically ill, according to the first randomized trial of its kind involving 237 adults from 10 hospitals in Wuhan, China.

from Latest Science News -- ScienceDaily https://ift.tt/2yaINPy
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists say most people need more protein than current guidelines suggest

A new review suggests that doing more exercise and eating more protein than current minimum recommendations may help people stay stronger, s...